Publications by authors named "Teja Thorat"

Claim this Profile
R
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center.
Marco Cipolli, Teja Thorat, Pia C Pafundi, Alessandro Roggeri, Daniela P Roggeri

Pulm Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.
Claire E Wainwright, Teja Thorat, Sarah Conner, Bradley S Quon, Jamie Duckers

J Cyst Fibros· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis.
Daniel Serrano, Alyssa Uzumcu, Maya Gerstein, Nicolai D Ayasse, Ella Engstrom, Teja Thorat

PLoS One· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis.
Christian Merlo, Teja Thorat, Lisa J McGarry, Christina V Scirica, Maral DerSarkissian

Pulm Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.
Christian A Merlo, Lisa J McGarry, Teja Thorat, Catherine Nguyen, Maral DerSarkissian

Thorax· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.
Christian A Merlo, Teja Thorat, Maral DerSarkissian, Lisa J McGarry, Catherine Nguyen

Thorax· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.
Craig McKinnon, Teja Thorat, Alexander Craft, Mark Higgins

BMJ Open Respir Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.
Nicholas J Simmonds, C Kors van der Ent, Carla Colombo, Nils Kinnman, Cynthia DeSouza, Teja Thorat

J Cyst Fibros· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and costs among children with cystic fibrosis in the United States.
Teja Thorat, Lisa J McGarry, Machaon M Bonafede, Brendan L Limone, Jaime L Rubin

Pediatr Pulmonol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States.
Teja Thorat, Lisa J McGarry, Krutika Jariwala-Parikh, Brendan Limone, Machaon Bonafede

Pulm Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review.
Jamie Duckers, Beth Lesher, Teja Thorat, Eleanor Lucas, Lisa J McGarry

J Clin Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Ellison Suthoff, Jochen G Mainz, Desmond W Cox, Teja Thorat, Daniel H Grossoehme

J Pediatr· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Teja Thorat, Peter J Neumann, James D Chambers

J Manag Care Spec Pharm· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Variability Seldom Assessed in Cost-effectiveness Studies.
Tara A Lavelle, David M Kent, Christine M Lundquist, Teja Thorat, Joshua T Cohen

Med Decis Making· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.
Alyssa Bilinski, Peter Neumann, Joshua Cohen, Teja Thorat, Katherine McDaniel

PLoS Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
James D Chambers, Teja Thorat, Colby L Wilkinson, Peter J Neumann

Health Aff (Millwood)· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.
Peter J Neumann, Teja Thorat, Yue Zhong, Jordan Anderson, Megan Farquhar

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval.
James D Chambers, Teja Thorat, Colby L Wilkinson, Mark Salem, Prasun Subedi

Appl Health Econ Health Policy· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Private payers disagree with Medicare over medical device coverage about half the time.
James D Chambers, Matthew Chenoweth, Teja Thorat, Peter J Neumann

Health Aff (Millwood)· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The lag from FDA approval to published cost-utility evidence.
James D Chambers, Teja Thorat, Junhee Pyo, Peter J Neumann

Expert Rev Pharmacoecon Outcomes Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The State of Cost-Utility Analyses in Asia: A Systematic Review.
Teja Thorat, Pei-Jung Lin, Peter J Neumann

Value Health Reg Issues· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing face of the cost-utility literature, 1990-2012.
Peter J Neumann, Teja Thorat, Jennifer Shi, Cayla J Saret, Joshua T Cohen

Value Health· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs.
James D Chambers, Teja Thorat, Junhee Pyo, Matthew Chenoweth, Peter J Neumann

Health Aff (Millwood)· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis